Comparison of the effect of Terazosin, Tolterodine, and their combination in the treatment of double J stent-related urinary symptoms in patients with ureteral stones
to evaluate the effect of Terazocine, Tolterodine and their combination in the treatment of double J stent-related urinary tract symptoms in patients with ureteral stones
Design
A phase 3, single-blinded, sham-controlled randomized clinical trial (RCT) with the parallel-groups design of 80 patients. Simple individual randomization was done using sealed envelopes.
Settings and conduct
The study was performed in the Ghaem hospital, Mashhad, Iran. It was a single-blind RCT in which the research participants were blinded to the randomization. Each group of patients received the allocated medication following transurethral lithotripsy and double J stent placement. The Ureteral Stent Symptoms Questionnaire (USSQ) questionnaire was used to evaluate the double J stent-related urinary tract symptoms after 2 weeks of stent placement.
Participants/Inclusion and exclusion criteria
inclusion criteria: patients with ureteral stones undergoing transurethral lithotripsy
exclusion criteria: History of major urinary surgery; Benign prostate hyperplasia under medical therapy; Overactive bladder; Drug sensitivity
Intervention groups
patients are randomized into 4 groups receiving the following medications respectively: Terazosin 2 mg twice a day, Tolterodine 2 mg twice a day, Terazocine+Tolterodine with the same dosage, and placebo
Comparison of the effect of Terazosin, Tolterodine, and their combination in the treatment of double J stent-related urinary symptoms in patients with ureteral stones
Public title
The effect of Terazosin and Tolterodine in the treatment of double J stent-related urinary symptoms
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
patients with ureteral stones undergoing unilateral transurethral lithotripsy
Exclusion criteria:
History of major urinary surgery
Benign prostate hyperplasia under medical therapy
Overactive bladder
Drug sensitivity
Age
From 20 years old to 60 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Sample size
Target sample size:
80
More than 1 sample in each individual
Number of samples in each individual:
20
4 groups: 20 patients in each group
Actual sample size reached:
20
Randomization (investigator's opinion)
Randomized
Randomization description
simple individual randomization using sealed envelopes
Blinding (investigator's opinion)
Single blinded
Blinding description
Research participants were blinded to the randomization. To maintain blindness, identical-looking medications and placebo without any label were used.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Mashhad University of Medical Sciences